Liposomal Bupivacaine vs. Bupivacaine Hydrochloride and Lidocaine During Suburethral Sling Placement

• Status: Completed
• Trial end date: 2018-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

Postoperative pain, the quality of their recovery and the opioid consumption following a midurethral sling placement are being compared between 2 groups. One group will have the hydro-dissection performed with a diluted liposomal bupivacaine solution. The other group will have the hydro-dissection performed with a diluted bupivacaine HCL and Lidocaine solution.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Atlantic Health System
• Treatments: Anesthetics; Bupivacaine; Lidocaine

Criteria

Inclusion Criteria:

• ASA physical status I-III

• Age >18 years

• Not Pregnant

• Able to give informed consent

• Electively chose surgical management of SUI with a suburethral sling

Exclusion Criteria:

• Pregnant or nursing

• Allergy to amide anesthetics

• History of drug or alcohol abuse

• Severe cardiovascular, hepatic, renal disease or neurological impairment,

• Long-acting opioid within 3 days or any opioid use within 24 hours before surgery

• Patients taking monoamineoxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types

• Contraindication to: Acetaminophen, Non-steroidal anti-inflammatory drugs (NSAID), Hydrocodone, Oxycodone, Hydromorphone AND Morphine,

• Administration of an investigational drug within 30 days before this study

• Chronic pain syndromes

• Daily NSAID or opioid use

• Patients undergoing concomitant procedures